Kyverna Therapeutics, Inc. (KYTX)

Market Cap	86.44M
Revenue (ttm)	n/a
Net Income (ttm)	-127.48M
Shares Out	43.22M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,240
Open	2.060
Previous Close	2.130
Day's Range	1.930 - 2.080
52-Week Range	1.780 - 17.550
Beta	n/a
Analysts	Buy
Price Target	18.80 (+840.0%)
Earnings Date	May 16, 2025

About KYTX

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company’s lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2024
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: KYTX
• Website: https://kyvernatx.com

Analyst Forecast

According to 5 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $18.8, which is an increase of 840.00% from the latest price.

Price Target

$18.8

(840.00% upside)

Analyst Consensus: Buy